Danaher Corporation (DHR) Stock

NYSE
HealthcareDiagnostics & Research Website

DHR has an Alpha Score of 40 out of 100 (weak), computed on Nov 21, 2026 from 3 of 4 sub-scores. 37 members of Congress disclosed 87 trades in DHR since 2014: 42 purchases and 45 sales, most recently Kevin Hern (partial sale, Sep 2, 2026). 9 of the hedge funds AlphaScala tracks reported DHR in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is Lone Pine Capital's at $1.10B. Company insiders reported 0 open-market buys and 6 sales on SEC Form 4 in the 90 days to Nov 20, 2026. Its trailing P/E ratio is 37.4 and its net margin 16.9% (key statistics as of Nov 9, 2026).

$220.36
-3.16%
Last price
Source: Finnhub
Alpha Score
40
Weak

What is DHR's Alpha Score?

How it works →

Alpha Score of 40 reflects weak overall profile with moderate momentum, poor value, moderate quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.

Momentum
52
Weak
Value
19
Poor
Quality
59
Moderate

Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.

Computed Nov 21, 2026

A rules-based research rating, not a recommendation to buy or sell.

Which members of Congress traded Danaher Corporation (DHR)?

Members
37
Disclosed trades
87
Purchases
42
Sales
45

Most recent: Kevin Hern (partial sale, Sep 2, 2026); records start Feb 25, 2014.

PoliticianTrade dateTypeAmount
Kevin Hern
R-OK · House
2026-09-02partial sale$1k – $15k
Kevin Hern
R-OK · House
2026-08-31sale$15k – $50k
Alan Armstrong
R-OK · Senate
2026-03-27purchase$1k – $15k
Julie Johnson
D-TX · House
2025-12-18sale$1k – $15k
Julie Johnson
D-TX · House
2025-11-13partial sale$1k – $15k
Julie Johnson
D-TX · House
2025-10-07purchase$1k – $15k
Lisa McClain
R-MI · House
2025-09-25sale$1k – $15k
Tom Kean Jr.
R-NJ · House
2025-09-03purchase$1k – $15k

From STOCK Act periodic transaction reports. House filings as of Nov 19, 2026.

Every member of Congress who traded DHR, with filing lags →

Which hedge funds own DHR?

From 13F filings
FundShares HeldPosition ValueChange vs prior Q
Lone Pine Capital
Steve Mandel
4.94M$1.10BNEW
Maverick Capital
Lee Ainslie
2.21M$490.30MNEW
Marshall Wace1.36M$302.14M+52575%
Tiger Global
Chase Coleman
1.27M$281.10M+178%
Millennium Management
Israel Englander
1.25M$276.12M-42%
Viking Global Investors
Andreas Halvorsen
1.04M$231.20MNEW
Citadel
Ken Griffin
725K$160.67M-23%
D.E. Shaw
David Shaw
462K$102.29M+12%
Bridgewater Associates
Ray Dalio
396K$87.79M+1443%

13F holdings as of Sep 30, 2026

Explore all tracked funds →

Are Danaher Corporation insiders buying or selling?

SEC Form 4 filings
90 days to Nov 20, 2026
Buys
0
Sells
6
Net $
-$13.4M
Unique insiders
3
DateInsiderRoleTypeSharesValue
Nov 9, 26Milosevich Gregory MExecutive Vice PresidentSELL2.1K$484K
Nov 9, 26Mcgrew MatthewExecutive Vice PresidentSELL17.4K$4.1M
Oct 28, 26Mcgrew MatthewExecutive Vice PresidentSELL14.2K$3.3M
Oct 28, 26Mcgrew MatthewExecutive Vice PresidentSELL15.6K$3.7M
Oct 28, 26Bouda ChristopherVP, Chief Accounting OfficerSELL4.3K$1.0M
Oct 28, 26Bouda ChristopherVP, Chief Accounting OfficerSELL3.3K$763K
Aug 21, 26Blair RainerPresident & CEOSELL11.3K$2.5M
Aug 21, 26Blair RainerPresident & CEOSELL39.2K$8.6M
Aug 21, 26Blair RainerPresident & CEOSELL7.8K$1.7M

SEC Form 4 filings as of Nov 20, 2026

See cluster-buy signals across all tickers →

What are DHR's key statistics?

P/E Ratio
37.40
EPS (TTM)
6.11
Dividend Yield
0.49%
Beta
0.77
Net Margin
16.91%
ROE
8.18%
Debt / Equity
0.35
52W High
$242.80
52W Low
$160.93

Key statistics as of Nov 9, 2026

How does DHR's valuation compare with the Healthcare sector?

MetricDHRHealthcare medianCompanies in median
P/E ratio37.429.1147
Net margin16.91%3.59%223
Return on equity8.18%3.41%255
Dividend yield (payers)0.49%1.37%61

Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 22, 2026). P/E excludes loss-making companies.

DHR price chart

Powered by TradingView

What does Danaher Corporation do?

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services globally, with a primary focus on the United States, China, and other international markets. Operating through three key segments—Biotechnology, Life Sciences, and Diagnostics—the company provides bioprocessing technologies, consumables, and solutions that accelerate therapeutic development and manufacturing, including cell culture media, chromatography resins, filtration systems, and single-use hardware for full manufacturing suites. Its Life Sciences division supports advanced research tools, while Diagnostics offers essential testing and healthcare filtration solutions. Originally founded in 1969 and transformed through strategic acquisitions and divestitures, such as the 2023 spin-off of its environmental solutions into Veralto, Danaher now concentrates on scientific instruments and consumables in the diagnostics and research sector. Employing around 62,000 to 63,000 people under CEO Rainer Blair, Danaher plays a pivotal role in the healthcare and life sciences industries, driving innovation in biopharma production and medical diagnostics with a strong emphasis on recurring revenue streams.

CEO
Mr. Rainer M. Blair
Employees
58,000
Market Cap
$161.99B
Ask about DHRAI research agent